

April 30, 2013



Oragenics To Present Oral Care Probiotics Seminar at SupplySide MarketPlace 2013

TAMPA, Fla.-- [Oragenics, Inc.](#) (NYSE:MKT: OGEN) today announced that Dr. Martin Handfield, Vice President of R&D for Oragenics, will be presenting a seminar entitled "Oral Care Probiotics Development" on Tuesday, April 30th at 5:00 pm at the SupplySide MarketPlace 2013, taking place from April 30 – May 2 at the Jacob Javits Center in New York, NY. SupplySide MarketPlace 2013 brings together the buyers and sellers that drive the dietary supplement, food, beverage, personal care, cosmetic and animal nutrition marketplaces. The Oragenics seminar is part of a practical short course entitled "Pre- & Probiotics Americas 2013: Pre- & Probiotics - Market, Science, Regulations and Applications" and will focus on describing the fundamental basis of oral probiotics, as well as highlighting the competitive advantage of the Oragenics line of oral care products.

Dr. John N. Bonfiglio, President and CEO, Oragenics, Inc., stated, "Dr Handfield will educate the attendees on the benefits of oral probiotics in maintaining good oral health and balance. He will outline the advantages of the Oragenics proprietary oral probiotic blend – [ProBiora3](#)®, which contains three strains of bacteria specifically chosen to work in the oral cavity."

About Oragenics, Inc.

Oragenics, Inc. is focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health for humans and pets. Oragenics has established an exclusive worldwide channel collaboration for lantibiotics, a novel class of broad spectrum antibiotics, with Intrexon Corporation Inc., a synthetic biology company. The collaboration will allow Oragenics access to Intrexon's proprietary technologies with the idea of accelerating the development of much needed new antibiotics that will work against resistant strains of bacteria. Oragenics also develops, markets and sells proprietary probiotics specifically designed to enhance oral health for humans and pets, under the brand names [Evora](#) and [ProBiora](#) in over 13 countries worldwide.

For more information about Oragenics, visit www.oragenics.com. Follow Oragenics on [Facebook](#) and [Twitter](#).

Safe Harbor Statement: *Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company's current views with*

respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to our ability to raise additional capital to sustain our operations beyond March 31, 2014 and those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Oragenics, Inc.

Corporate Contact

Michael Sullivan, 813-286-7900 x246

Chief Financial Officer

Direct: 813-786-6431

msullivan@oragenics.com

or

Investor / Media Contacts

The Ruth Group

Stephanie Carrington / Aaron Estrada, +1-646-536-7017/7028

scarrington@theruthgroup.com

aestrada@theruthgroup.com

Source: Oragenics, Inc.